Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Globe Newswire (Fri, 26-Jun 8:35 AM ET)
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Globe Newswire (Tue, 23-Jun 8:35 AM ET)
Nasus Pharma to Participate in the Zacks Life Sciences Investor Forum
Globe Newswire (Mon, 22-Jun 8:00 AM ET)
Globe Newswire (Tue, 9-Jun 8:00 AM ET)
Globe Newswire (Mon, 1-Jun 8:00 AM ET)
Nasus Pharma to Participate in Upcoming Investor Conferences
Globe Newswire (Fri, 1-May 9:14 AM ET)
NSRX’s Phase 2 Study: NS002 Delivers Epinephrine Twice as Fast as EpiPen® in Critical Minutes
Market Chameleon (Mon, 16-Mar 3:51 AM ET)
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
Nasus Pharma Ltd. trades on the AMEX stock market under the symbol NSRX.
As of June 26, 2026, NSRX stock price climbed to $3.32 with 22,437 million shares trading.
NSRX has a beta of 1.62, meaning it tends to be more sensitive to market movements. NSRX has a correlation of 0.03 to the broad based SPY ETF.
NSRX has a market cap of $38.88 million. This is considered a Sub-Micro Cap stock.
NSRX support price is $3.08 and resistance is $3.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NSRX shares will trade within this expected range on the day.
